These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30920187)

  • 21. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
    Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
    J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.
    Dreifuss JA; Griffin ML; Frost K; Fitzmaurice GM; Potter JS; Fiellin DA; Selzer J; Hatch-Maillette M; Sonne SC; Weiss RD
    Drug Alcohol Depend; 2013 Jul; 131(1-2):112-8. PubMed ID: 23333292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone.
    Hser YI; Huang D; Saxon AJ; Woody G; Moskowitz AL; Matthews AG; Ling W
    J Addict Med; 2017; 11(1):63-69. PubMed ID: 27898496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
    Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
    Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
    Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
    Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
    Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
    Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
    Zhu Y; Mooney LJ; Yoo C; Evans EA; Kelleghan A; Saxon AJ; Curtis ME; Hser YI
    Drug Alcohol Depend; 2021 Nov; 228():108996. PubMed ID: 34555691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
    McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
    Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.
    Mullins N; Galvin SL; Ramage M; Gannon M; Lorenz K; Sager B; Coulson CC
    J Addict Med; 2020; 14(3):185-192. PubMed ID: 31567599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.